NASDAQ$VCEL
Vericel Corporation · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported second quarter financial results and raised full-year financial guidance.
Vericel Corporation reported a record second quarter with total revenue of $45.9 million, a 24% increase compared to the prior year. The company raised its full-year 2023 revenue guidance to $190-197 million.
- Total net revenue reached a record $45.9 million, representing 24% growth versus the prior year.
- MACI net revenue grew by 27% to $36.3 million.
- Epicel net revenue increased by 17% to $9.6 million.
- The company had approximately $147 million in cash, restricted cash and investments, with no debt as of June 30, 2023.
Headline financials
Revenue & EPS history
Vericel · Revenue · Quarterly
$45.9M
Revenue by segment
Vericel · $45.9M total across 2 segments · Q2 2023
- MACI$36.3M+26.9%79.1%
- Epicel$9.6M+17.1%20.9%
Forward guidance
Vericel expects total net revenue for 2023 to be in the range of $190 to $197 million and maintains profitability guidance of gross margin in the high-60% range and adjusted EBITDA margin in the mid-teens % range.
Tailwinds
- Total net revenue for 2023 now expected to be in the range of $190 to $197 million compared to the previous guidance of $184 to $192 million
- Maintaining profitability guidance of gross margin in the high-60% range
- Maintaining adjusted EBITDA margin in the mid-teens % range
- Further acceleration in total company revenue growth in 2024 driven by the planned launch of arthroscopic MACI
- Significant contribution from NexoBrid expected in 2024
Headwinds
- Uncertainties associated with expectations regarding future revenue
- Uncertainties associated with growth in revenue, market penetration for MACI, Epicel, and NexoBrid
- Uncertainties associated with growth in profit, gross margins and operating margins
- The ability to continue to scale manufacturing operations to meet the demand for cell therapy products
- Potential fluctuations in sales and volumes and results of operations over the course of the year
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+1.4%
Avg return
Earnings day
+2.8%
Avg return
5 days after
+2.2%
Avg return
30 days after
47%
30 / 64 earnings
Positive
+48.1%
Q3 2018
Best reaction
-30.0%
Q2 2013
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.6% | -10.4% | -1.4% | |
| Q4 2025 | +1.7% | -7.3% | -20.9% | |
| Q3 2025 | +4.6% | +10.3% | -2.6% | |
| Q1 2025 | +3.2% | +7.8% | +7.0% | |
| Q4 2024 | -6.1% | -3.2% | -15.8% | |
| Q3 2024 | +12.4% | +16.3% | +17.3% | |
| Q2 2024 | -5.7% | -7.5% | +2.2% | |
| Q1 2024 | -1.8% | -2.0% | -10.4% | |
| Q4 2023 | -6.5% | -7.0% | +8.8% | |
| Q3 2023 | -11.2% | -7.0% | -7.3% | |
| Q2 2023 | -8.9% | -9.2% | -3.5% | |
| Q1 2023 | +0.5% | +2.8% | +6.5% | |
| Q4 2022 | +6.9% | +6.6% | +1.6% | |
| Q3 2022 | -2.8% | +0.2% | -0.3% | |
| Q2 2022 | -4.3% | -6.2% | -28.7% | |
| Q1 2022 | -9.1% | -18.9% | -13.1% | |
| Q4 2021 | +21.9% | +26.4% | +11.2% | |
| Q3 2021 | -2.7% | -3.0% | -10.6% | |
| Q2 2021 | -2.1% | -4.5% | +9.0% | |
| Q1 2021 | -10.2% | -15.9% | -5.8% | |
| Q4 2020 | +0.4% | +1.7% | +9.0% | |
| Q3 2020 | +6.0% | +17.7% | +18.5% | |
| Q2 2020 | -9.8% | -5.0% | -5.5% | |
| Q1 2020 | +5.6% | +8.3% | +3.9% | |
| Q4 2019 | -20.4% | -18.3% | -46.9% | |
| Q3 2019 | +15.3% | +15.7% | +12.9% | |
| Q2 2019 | +2.4% | +1.9% | -8.3% | |
| Q1 2019 | -2.5% | -3.6% | -16.8% | |
| Q4 2018 | -7.4% | -3.5% | -13.6% | |
| Q3 2018 | +48.1% | +39.6% | +53.3% | |
| Q2 2018 | +25.6% | +27.1% | +36.5% | |
| Q1 2018 | +6.0% | +5.6% | +0.4% | |
| Q4 2017 | +40.1% | +38.3% | +33.5% | |
| Q3 2017 | -7.0% | -5.8% | +14.0% | |
| Q2 2017 | +11.7% | +21.7% | +48.3% | |
| Q1 2017 | +0.0% | +3.9% | +5.9% | |
| Q4 2016 | -1.7% | +0.0% | -6.9% | |
| Q3 2016 | -2.3% | +4.7% | +9.3% | |
| Q2 2016 | -5.5% | -7.7% | -5.5% | |
| Q1 2016 | +11.5% | — | — | |
| Q4 2015 | +4.8% | — | — | |
| Q3 2015 | -9.7% | — | — | |
| Q2 2015 | +4.3% | — | — | |
| Q1 2015 | -2.5% | — | — | |
| Q4 2014 | +2.9% | — | — | |
| Q3 2014 | +3.6% | — | — | |
| Q2 2014 | -0.3% | — | — | |
| Q1 2014 | +0.5% | — | — | |
| Q4 2013 | -12.7% | — | — | |
| Q3 2013 | -2.2% | — | — | |
| Q2 2013 | -30.0% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q4 2012 | -6.3% | — | — | |
| Q3 2012 | -4.0% | — | — | |
| Q2 2012 | -6.5% | — | — | |
| Q1 2012 | -0.8% | — | — | |
| Q4 2011 | +1.0% | — | — | |
| Q3 2011 | +3.1% | — | — | |
| Q2 2011 | +8.3% | — | — | |
| Q1 2011 | +4.7% | — | — | |
| Q4 2009 | +4.7% | — | — | |
| Q3 2010 | +35.3% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +1.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro